<DOC>
	<DOC>NCT02890953</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of a single intraventricular administration of Pneumostem® for treatment of Intraventricular hemorrhage (IVH) in high-risk premature infants by comparing Pneumostem-treated group with a control group.</brief_summary>
	<brief_title>Efficacy and Safety of Pneumostem® for IVH in Premature Infants (Phase 2a)</brief_title>
	<detailed_description />
	<criteria>IVH grade 34 age : within postnatal day 28 gestational age: 23&lt;34 weeks Patient with severe congenital abnormalities Patient with antenatal brain hemorrhage Patient with asphyxia or Hypoxic ischemic encepalophathy Patient with chromosome anomalies (i.e. Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital malformation (Hydrocephalus, Encephalocele, etc) Patient with a concurrent severe congenital infection (i.e. Herpes, Toxoplasmosis, Rubella, Syphilis, AIDS, etc) Patient withCRP &gt; 30 mg/dL; Severe sepsis or shock Patient with severe intracranial hemorrhage ≥ grade 3 or 4 Patient with a history of participating in other clinical studies Patient who is considered inappropriate to participate in the study by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>